Alimera Sciences announces that the National Institute for Health and Care Excellence, NICE, has issued Final Draft Guidance recommending that patients with a natural lens being treated for chronic diabetic macular edema, DME, have access to ILUVIEN 190 microgram intravitreal implant in applicator. “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “These patients represent up to 75% of the overall DME population in the United Kingdom* who will now potentially have access to ILUVIEN to help control the recurrence of the disease for up to 36 months. We look forward to the publication of Final Guidance shortly.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
- Alimera Sciences completes recruitment for the Synchronicity Study
- Alimera Sciences names Maltz as Chief Financial Officer
- Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
